NCT03083158已完成4 期
Identification of Age-dependent Mechanism of Vaccine-induced Immunity to a Single Dose of Hepatitis B Vaccine Using a Systems Biology Approach - a Demonstration Project
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Antibody response to the first dose of hepatitis B vaccine
研究概览
简要总结
Infection and cancer is a major cause of death and morbidity, and may be preventable through vaccination. It is not fully understood at the molecular level why some people respond better than others to vaccines until now the technology to assess this has not been available. This has impaired vaccine development. The overall goal of the Human Vaccines Project is to understand the 'rules' of how vaccines work. In this demonstration project the investigators will vaccinate healthy adults with hepatitis B vaccine to start to understand better how it works, ultimately helping with rational vaccine design in the future.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult, corresponding to one of the study age groups.
- •No history of hepatitis B disease.
- •No prior receipt of any hepatitis B-containing vaccine.
- •Undetectable level of anti-HBs and anti-HBc antibody and HBs antigen at study enrolment (indicating no evidence of prior hepatitis B vaccination or infection).
- •Generally good health (stable chronic conditions acceptable), living independently or with minimal assistance (Clinical Frailty score 1-5) and able to attend clinic appointments.
- •Willing and able to comply with the requirements of the protocol.
- •Has given informed consent for participation in the study.
排除标准
- •The participant may not enter the study if ANY of the following apply:
- •Individual who is on the delegation log for this study
- •History of being a household contact of a known hepatitis B-infected individual.
- •Planned administration of any vaccine not specified in the study protocol from 1 month pre- to the 1 month post-1st dose of vaccine.
- •Planned receipt of any investigational drug for the duration of the study.
- •Confirmed or suspected immunodeficiency.
- •A family history of congenital or hereditary immunodeficiency.
- •Receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid) in the 3 months prior to dose 1 of vaccine. Nasal, topical or inhaled steroids are allowed.
- •Currently taking any anti-platelet or anti-coagulant medications (does not include daily low-dose aspirin).
- •Bleeding disorder or thrombocytopenia, that contraindicates IM injection, blood collection and/or lymph node fine needle aspiration.
- •Administration of immunoglobulins within the prior 12 months and/or any other blood products within the prior 3 months or planned during the study period.
- •Current pregnancy or planning to become pregnant in the 6 months post-dose 1 vaccination.
- •History of allergy to any component of the vaccine.
- •Unstable medical condition, as indicated by a requirement for hospitalization or a substantial medication change to stabilize said condition within previous 3 months.
- •History of any neurologic disorders or seizures, including a history of Guillain-Barre syndrome.
- •Clinical Frailty score of 6-7 (moderately frail or severely frail).
- •Scheduled elective surgery or other procedures requiring general anaesthesia from 1 month pre- to the 1 month post-1st dose of vaccine.
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- •Temporary exclusion if acute symptomatic illness in the 7 days prior to planned first vaccine dose - vaccination will be delayed, but participant can remain in the study.
研究组 & 干预措施
Group 1
Other
Older adults, aged 61-80 years
干预措施: Hepatitis B vaccine (Drug)
Group 2
Other
Younger adults, aged 40-60 years
干预措施: Hepatitis B vaccine (Drug)
结局指标
主要结局
Antibody response to the first dose of hepatitis B vaccine
时间窗: 28 days post-vaccination following the first dose of vaccine
Anti-HBs antibody level
次要结局
- Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to cellular immune response(Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination)
- Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to lymph node response(Pre-vaccine and 14 days following first dose only)
- Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to epigenetic response(Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination)
- Identify the DNA sequence of B- and T- cell receptors following vaccination(Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination)
- Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to transcriptomic response(Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination)
- Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to proteomic response(Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination)
- Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to metabalomic response(Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination)
研究者
Manish Sadarangani
Principle Investigator
University of British Columbia
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)InfluenzaHerpes ZosterNCT05082688Radboud University Medical Center148
已完成
不适用
Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).SarcomaNCT02553954Centre Oscar Lambret58
进行中（未招募）
不适用
Immunity to Infection in Healthy Participants and Participants With CancerSARS-CoV-2Hematologic MalignancyInfluenzaSolid TumorNCT05787964University Hospital Tuebingen200
招募中
2 期
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric PatientsPediatric CancerNCT04948619Wake Forest University Health Sciences64
已完成
4 期
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19Covid19NCT05047718Centre Hospitalier Universitaire de Saint Etienne54